New Zohydro ER Formulation Launched

Share this content:
The FDA approved the new formulation earlier this year.
The FDA approved the new formulation earlier this year.

Pernix announced the launch of a new formulation of Zohydro ER (hydrocodone bitartrate extended-release capsules) with BeadTek, a new abuse-deterrent technology.

The new formulation included BeadTek, which is an indistinguishable mix of inactive beads, active immediate-release hydrocodone beads, and active extended-release hydrocodone beads. 

The inactive beads remain inert and dissolve independently of the active hydrocodone beads. 

The inactive beads are designed not to change the 12-hour release properties of the medication when taken as directed, but will immediately form a viscous gel when crushed and dissolved in liquids or solvents.

Zohydro ER with BeadTek is a Schedule II opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment (eg, non-opioid analgesics or immediate-release opioids) are inadequate.

Zohydro ER capsules with BeadTek are available in 10mg, 15mg, 20mg, 30mg, 40mg, and 50mg strengths.

The FDA approved the new formulation earlier this year. 

You must be a registered member of Clinical Pain Advisor to post a comment.